Rasmus Sejersten Ripa

List of Publications by Year
in descending order

77 papers	2,018 citations	331538 21 h-index	254106 43 g-index
79 all docs	79 docs citations	79 times ranked	2584 citing authors

#	Article	IF	Citations
1	Myocardial perfusion recovery induced by an Î±-calcitonin gene-related peptide analogue. Journal of Nuclear Cardiology, 2022, 29, 2090-2099.	1.4	5
2	Amiodarone attenuates cardiac Rubidium-82 in consecutive PET/CT scans in a rodent model. Journal of Nuclear Cardiology, 2022, 29, 2853-2862.	1.4	4
3	Liraglutide Lowers Palmitoleate Levels in Type 2 Diabetes. A Post Hoc Analysis of the LIRAFLAME Randomized Placebo-Controlled Trial. Frontiers in Clinical Diabetes and Healthcare, 2022, 3, .	0.3	0
4	In vivo detection of urokinase-type plasminogen activator receptor (uPAR) expression in arterial atherogenesis using [64Cu]Cu-DOTA-AE105 positron emission tomography (PET). Atherosclerosis, 2022, 352, 103-111.	0.4	2
5	Editorial: Advanced Cardiovascular Imaging in Diabetes. Frontiers in Endocrinology, 2022, 13, 848975.	1.5	0
6	Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis, 2022, 352, 88-95.	0.4	13
7	The effect of liraglutide on cardiac autonomic function in type 2 diabetes: A prespecified secondary analysis from the <scp>LIRAFLAME</scp> randomized, doubleâ€blinded, placeboâ€controlled trial. Diabetes, Obesity and Metabolism, 2022, 24, 1638-1642.	2.2	1
8	Nonâ€invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls. Diabetic Medicine, 2021, 38, e14517.	1.2	4
9	Flow Cytometric Evaluation of the Ongoing Angiogenic Response in Rat Cardiac Tissue Following Myocardial Infarction. Current Protocols, 2021, 1, e40.	1.3	1
10	Carotid plaque inflammatory activity assessed by 2-[18F]FDG-PET imaging decrease after a neurological thromboembolic event. EJNMMI Research, 2021, 11, 30.	1.1	0
11	Effect of Liraglutide on Arterial Inflammation Assessed as [¹⁸ F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial. Circulation: Cardiovascular Imaging, 2021, 14, e012174.	1.3	18
12	Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE. Diagnostics, 2021, 11, 1431.	1.3	5
13	Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the <scp>LIRAFLAME</scp> randomized <scp>placeboâ€controlled</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 2651-2659.	2.2	7
14	Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Research and Care, 2021, 9, e002395.	1.2	14
15	Effect of liraglutide on expression of inflammatory genes in type 2 diabetes. Scientific Reports, 2021, 11, 18522.	1.6	21
16	The Initial Cardiac Tissue Response to Cryopreserved Allogeneic Adipose Tissue-Derived Mesenchymal Stromal Cells in Rats with Chronic Ischemic Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 11758.	1.8	5
17	Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial. Frontiers in Endocrinology, 2021, 12, 790405.	1.5	16
18	The Association Between Cardiovascular Autonomic Function and Changes in Kidney and Myocardial Function in Type 2 Diabetes and Healthy Controls. Frontiers in Endocrinology, 2021, 12, 780679.	1.5	4

#	Article	IF	Citations
19	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. Journal of Nuclear Cardiology, 2020, 27, 1698-1707.	1.4	15
20	123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. Journal of Nuclear Cardiology, 2020, 27, 931-939.	1.4	5
21	18F-FDG PET/MR-imaging in a GÃ¶ttingen Minipig model of atherosclerosis: Correlations with histology and quantitative gene expression. Atherosclerosis, 2019, 285, 55-63.	0.4	12
22	Symptomatic Carotid Plaques Show Decreased (18)F-Fluorodeoxyglucose (FDG) Uptake on Positron Emission Tomography (PET) After 3 Months Follow-up from Last Symptom. European Journal of Vascular and Endovascular Surgery, 2019, 58, e621-e622.	0.8	0
23	Genetic associations and regulation of expression indicate an independent role for 14q32 snoRNAs in human cardiovascular disease. Cardiovascular Research, 2019, 115, 1519-1532.	1.8	25
24	Early risk stratification using Rubidium-82 positron emission tomography in STEMI patients. Journal of Nuclear Cardiology, 2019, 26, 471-482.	1.4	4
25	Rubidium-82 PET imaging is feasible in a rat myocardial infarction model. Journal of Nuclear Cardiology, 2019, 26, 798-809.	1.4	12
26	Subacute cardiac rubidium-82 positron emission tomography (82Rb-PET) to assess myocardial area at risk, final infarct size, and myocardial salvage after STEMI. Journal of Nuclear Cardiology, 2018, 25, 970-981.	1.4	6
27	¹²³Iâ€<scp>MIBG</scp> imaging for detection of anthracyclineâ€induced cardiomyopathy. Clinical Physiology and Functional Imaging, 2018, 38, 176-185.	0.5	12
28	Cardiac Microvascular Dysfunction in Women Living With HIV Is Associated With Cytomegalovirus Immunoglobulin G. Open Forum Infectious Diseases, 2018, 5, ofy205.	0.4	10
29	Retention and Functional Effect of Adipose-Derived Stromal Cells Administered in Alginate Hydrogel in a Rat Model of Acute Myocardial Infarction. Stem Cells International, 2018, 2018, 1-13.	1.2	12
30	Perfusion imaging using rubidium-82 (82Rb) PET in rats with myocardial infarction: First small animal cardiac 82Rb-PET. Journal of Nuclear Cardiology, 2017, 24, 750-752.	1.4	7
31	Comparison of the Peripheral Reactive Hyperemia Index with Myocardial Perfusion Reserve by 82Rb PET/CT in HIV-Infected Patients. Diagnostics, 2017, 7, 31.	1.3	6
32	Microbiota-Dependent Marker TMAO is Not Associated With Decreased Myocardial Perfusion in Well-Treated HIV-Infected Patients as Assessed by 82Rubidium PET/CT. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e83-e85.	0.9	10
33	PET/MR Imaging in Vascular Disease. PET Clinics, 2016, 11, 479-488.	1.5	6
34	Abstract 460: ⁶⁴ Cu-DOTATATE for in vivo Positron Emission Tomography Imaging of Somatostatin Receptor 2 Expressing Macrophages in a GÃ¶ttingen Minipig Model of Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, .	1.1	0
35	Normal Myocardial Flow Reserve in HIV-Infected Patients on Stable Antiretroviral Therapy. Medicine (United States), 2015, 94, e1886.	0.4	15
36	Imaging Atherosclerosis with Hybrid Positron Emission Tomography/Magnetic Resonance Imaging. BioMed Research International, 2015, 2015, 1-8.	0.9	14

#	Article	IF	Citations
37	⁶⁴ Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1696-1703.	1.1	108
38	⁶⁴Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with ⁶⁸Ga-DOTATOC in 60 Patients. Journal of Nuclear Medicine, 2015, 56, 1895-1900.	2.8	67
39	HIV infection and arterial inflammation assessed by 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET): A prospective cross-sectional study. Journal of Nuclear Cardiology, 2015, 22, 372-380.	1.4	24
40	(18)F-FDG PET imaging in detection of radiation-induced vascular disease in lymphoma survivors. American Journal of Nuclear Medicine and Molecular Imaging, 2015, 5, 408-15.	1.0	3
41	Positron emission tomography of the vulnerable atherosclerotic plaque in man â€“ a contemporary review. Clinical Physiology and Functional Imaging, 2014, 34, 413-425.	0.5	11
42	Non-Invasive Imaging for Subclinical Coronary Atherosclerosis in Patients with Peripheral Artery Disease. Current Atherosclerosis Reports, 2014, 16, 415.	2.0	9
43	Feasibility of simultaneous PET/MR in diet-induced atherosclerotic minipig: a pilot study for translational imaging. American Journal of Nuclear Medicine and Molecular Imaging, 2014, 4, 448-58.	1.0	12
44	Association between lectin complement pathway initiators, C-reactive protein and left ventricular remodeling in myocardial infarctionâ€"A magnetic resonance study. Molecular Immunology, 2013, 54, 408-414.	1.0	27
45	Small animal positron emission tomography imaging and <i>in vivo</i> studies of atherosclerosis. Clinical Physiology and Functional Imaging, 2013, 33, 173-185.	0.5	4
46	Clinical outcome after stem cell mobilization with granulocyte-colony-stimulating factor after acute ST-elevation myocardial infarction: 5-year results of the STEMMI trial. Scandinavian Journal of Clinical and Laboratory Investigation, 2013, 73, 125-129.	0.6	7
47	Silent Ischemic Heart Disease and Pericardial Fat Volume in HIV-Infected Patients: A Case-Control Myocardial Perfusion Scintigraphy Study. PLoS ONE, 2013, 8, e72066.	1.1	30
48	Feasibility of simultaneous PET/MR of the carotid artery: first clinical experience and comparison to PET/CT. American Journal of Nuclear Medicine and Molecular Imaging, 2013, 3, 361-71.	1.0	53
49	18F-FDG PET Imaging of Murine Atherosclerosis: Association with Gene Expression of Key Molecular Markers. PLoS ONE, 2012, 7, e50908.	1.1	40
50	Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease. Danish Medical Journal, 2012, 59, B4411.	0.5	7
51	Mesenchymal stromal cell derived endothelial progenitor treatment in patients with refractory angina. Scandinavian Cardiovascular Journal, 2011, 45, 161-168.	0.4	69
52	The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. Inflammation Research, 2011, 60, 281-287.	1.6	46
53	Serial in vivo imaging of the porcine heart after percutaneous, intramyocardially injected 111In-labeled human mesenchymal stromal cells. International Journal of Cardiovascular Imaging, 2010, 26, 273-284.	0.7	19
54	Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation, 2010, 70, 80-86.	0.6	31

#	Article	IF	Citations
55	Instent neointimal hyperplasia after percutaneous intervention for ST-elevation myocardial infarction and treatment with granulocyte-colony stimulating factor. Results from the stem cells in myocardial infarction (STEMMI) trial. International Journal of Cardiology, 2010, 139, 269-275.	0.8	6
56	Timing of granulocyte-colony stimulating factor treatment after acute myocardial infarction and recovery of left ventricular function: Results from the STEMMI trial. International Journal of Cardiology, 2010, 140, 351-355.	0.8	13
57	REGENT trialâ€"the end of cell therapy for MI?. Nature Reviews Cardiology, 2009, 6, 567-568.	6.1	6
58	The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease. Scandinavian Journal of Clinical and Laboratory Investigation, 2009, 69, 722-728.	0.6	10
59	G-CSF therapy with mobilization of bone marrow stem cells for myocardial recovery after acute myocardial infarctionâ€"A relevant treatment?. Experimental Hematology, 2008, 36, 681-686.	0.2	20
60	Comparison of infarct size changes with delayed contrast-enhanced magnetic resonance imaging and electrocardiogram QRS scoring during the 6 months after acutely reperfused myocardial infarction. Journal of Electrocardiology, 2008, 41, 609-613.	0.4	21
61	Stem Cell Mobilization by Granulocyte Colony-Stimulating Factor for Myocardial Recovery After Acute Myocardial Infarction. Journal of the American College of Cardiology, 2008, 51, 1429-1437.	1.2	136
62	YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scandinavian Cardiovascular Journal, 2008, 42, 295-302.	0.4	93
63	Release of biomarkers of myocardial damage after direct intramyocardial injection of genes and stem cells via the percutaneous transluminal route. European Heart Journal, 2008, 29, 1819-1826.	1.0	38
64	Mobilization of haematopoietic and non-haematopoietic cells by granulocyte-colony stimulating factor and vascular endothelial growth factor gene therapy in patients with stable severe coronary artery disease. Scandinavian Cardiovascular Journal, 2007, 41, 397-404.	0.4	4
65	Bone Marrowâ€"Derived Mesenchymal Cell Mobilization by Granulocyte-Colony Stimulating Factor After Acute Myocardial Infarction. Circulation, 2007, 116, I24-30.	1.6	101
66	Timing of ischemic onset estimated from the electrocardiogram is better than historical timing for predicting outcome after reperfusion therapy for acute anterior myocardial infarction: A DANish trial in Acute Myocardial Infarction 2 (DANAMI-2) substudy. American Heart Journal, 2007, 154, 61.e1-61.e8.	1.2	28
67	Short- and long-term changes in myocardial function, morphology, edema, and infarct mass after ST-segment elevation myocardial infarction evaluated by serial magnetic resonance imaging. American Heart Journal, 2007, 154, 929-936.	1.2	70
68	Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease â€" Indicators of myocardial ischemic burden?. International Journal of Cardiology, 2007, 120, 181-187.	0.8	14
69	Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. European Heart Journal, 2006, 27, 1785-1792.	1.0	136
70	In-stent neo-intimal hyperplasia after stem cell mobilization by granulocyte-colony stimulating factor. International Journal of Cardiology, 2006, 111, 174-177.	0.8	38
71	Usefulness of Quantitative Baseline ST-Segment Elevation for Predicting Outcomes After Primary Coronary Angioplasty or Fibrinolysis (Results from the DANAMI-2 Trial). American Journal of Cardiology, 2006, 97, 611-616.	0.7	19
72	Epo 'cytokine-doping' of heart disease patients, will it work?. European Heart Journal, 2006, 27, 1767-1768.	1.0	5

#	Article	IF	Citations
73	Myocardial regeneration induced by granulocyte-colony-stimulating factor mobilization of stem cells in patients with acute or chronic ischaemic heart disease: a non-invasive alternative for clinical stem cell therapy?. European Heart Journal, 2006, 27, 2748-2754.	1.0	37
74	Stem Cell Mobilization Induced by Subcutaneous Granulocyte-Colony Stimulating Factor to Improve Cardiac Regeneration After Acute ST-Elevation Myocardial Infarction. Circulation, 2006, 113, 1983-1992.	1.6	331
75	Comparison between human and automated electrocardiographic waveform measurements for calculating the Anderson-Wilkins acuteness score in patients with acute myocardial infarction. Journal of Electrocardiology, 2005, 38, 96-99.	0.4	19
76	Presymptomatic diagnosis using a deletion of a single codon in families with hereditary non-polyposis colorectal cancer. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 570, 89-96.	0.4	6
77	Safety of Bone Marrow Stem Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor: 30 Daysâ€™ Blinded Clinical Results from the Stem Cells in Myocardial Infarction (STEMMI) Trial. Cardiology, 2005, 5, 177-182.	0.3	9